Rome hosted the 21st Congress of the European Association of Neuro-Oncology (EANO) from 24 to 27 September, bringing together experts in the research, diagnosis and treatment of nervous system tumours at one of Europe's most important neuro-oncology meetings. Researchers from all three NICR nodes were also among the active participants.

Cancer treatment not only damages tumour cells but also changes them. And some of these changes could be used to target treatment more effectively. Scientists from the team of Marek Mráz at CEITEC Masaryk University and University Hospital Brno, which is part of the NICR, have found that during treatment for chronic lymphocytic leukaemia, a receptor becomes more abundant on the surface of cancer cells, making it possible to target them with an antibody.